Company profile: EryDel
1.1 - Company Overview
Company description
- Provider of red blood cell-based drug delivery technologies and therapies. Offers the AIDE platform for autologous intracellular drug encapsulation, the CE marked Red Cell Loader device and EryKit for point-of-care loading, and EryDex, a patient-specific dexamethasone sodium phosphate treatment for Ataxia-Telangiectasia; conducting the NEAT Phase 3 trial evaluating EryDex's neurological effects.
Products and services
- AIDE Technology Platform: Engineers a custom-engineered autologous intracellular encapsulation system that loads drugs, proteins, contrast agents, and nanoparticles into patient erythrocytes for progressive in vivo therapeutic release
- EryDex: Produces an autologous treatment for Ataxia‑Telangiectasia that uses a patient’s red blood cells to deliver dexamethasone sodium phosphate (DSP) progressively over a once‑monthly period
- Red Cell Loader (RCL): Constructs a CE‑marked device that automates AIDE by handling blood, drug, and processing solutions at the point of care for standardized encapsulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to EryDel
Cellectar Biosciences
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer therapies and diagnostics, designing phospholipid drug conjugates that target tumor cells to detect, treat, and monitor cancers. Lead candidate iopofosine I 131 is in Phase 2/1 studies. Pipeline includes CLR 1900 cytotoxic compounds and collaborative PDC programs (CLR 2000, CLR 12120) with Avicenna and Orano Med, plus new PDCs with IntoCell and LegoChemBio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellectar Biosciences company profile →
Haselmeier
HQ: Germany
Website
- Description: Provider of innovative self-injection devices, including pen injectors and other systems for self injection, featuring proprietary designs, technology and intellectual property. With over four decades of medical device experience, the company offers a world-class design and development team working in compliance with regulatory requirements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Haselmeier company profile →
Liquidia
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for pulmonary hypertension. Portfolio includes investigational treprostinil products YUTREPIA (inhaled dry powder) and L606 (sustained-release liposomal via next-generation nebulizer) for PAH and PH-ILD; a fully substitutable generic treprostinil injection for PAH promoted with Sandoz; and PRINT Technology to create precise drug particles for enhanced lung delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Liquidia company profile →
Arecor Therapeutics
HQ: United Kingdom
Website
- Description: Provider of innovative biopharmaceutical formulation technology, leveraging a platform to develop proprietary products that enable improved treatments for diabetes care through the innovative reformulation of approved proteins and peptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arecor Therapeutics company profile →
Elutia
HQ: United States
Website
- Description: Provider of customized tissue products, including CanGaroo, an acellular envelope for securing implantable electronic devices to promote healthy tissue integration and wound healing; SimpliDerm, a human acellular dermal matrix for soft tissue reconstruction with rapid integration and revascularization and a low inflammatory response; and CanGarooRM, a next-generation drug-eluting biomatrix for securing cardiac devices or neurostimulators.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elutia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for EryDel
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to EryDel
2.2 - Growth funds investing in similar companies to EryDel
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for EryDel
4.2 - Public trading comparable groups for EryDel
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →